Biotech and Pharma Industry News | BioPharma Dive
BioPharma Dive provides news and analysis for biotech and biopharmaceutical executives. We cover topics like clinical trials, drug discovery and development, pharma marketing, FDA approvals and regulations, and more.
The top biopharma conferences in 2025 | BioPharma Dive
Oct 1, 2024 · American Association of Cancer Research Annual Meeting. April 25 - 30, 2025 Chicago. While the American Society of Clinical Oncology’s meeting often gets billed as the field’s largest conference, AACR has become an equally major gathering for cancer research, particularly earlier-stage findings on new drug mechanisms of action or treatment modalities.
Drugmakers are racing to find the next Wegovy. These obesity …
Oct 10, 2024 · Within the pharmaceutical industry, a multibillion-dollar race is underway to top Novo Nordisk’s and Eli Lilly’s in-demand obesity drugs. Dozens of companies, large and small, have set out to test experimental medicines they claim could be more potent, convenient or have fewer side effects than Novo’s Wegovy and Lilly’s Zepbound.
Biotech IPOs are the industry’s lifeblood. Track how they’re …
Dec 3, 2024 · Methodology. For this database, BioPharma Dive includes biotech companies that raised funds in an initial public offering on a U.S. stock exchange.
Biotech startups are built on venture capital. Track funding rounds ...
Nov 21, 2024 · Drug development is an expensive, risky endeavor. Biotechnology companies just starting out are many years away from seeing profits, if ever. So more often than not, a startup’s success turning science into medicines can come down to how much money it raises.
Novartis wagers more than $1B on gene therapies for the nervous …
Nov 21, 2024 · The Kate acquisition comes almost a year and a half after Novartis agreed to buy DTx Pharma, a startup aiming to use RNA drugmaking technology to treat neurological diseases. The deal, which carried a $500 million upfront payment, handed Novartis a few experimental drugs that had yet to reach human testing.
Biotech M&A has plateaued. Track the deals that are happening …
Dec 30, 2024 · Methodology. For this database, BioPharma Dive looked only at companies developing human medicines. The mergers and acquisitions included in the database are limited by certain criteria, namely that they must be for an entire company — not for product licensings, options to acquire or for partial equity stakes.
Drug patents protect pharma profits. Track when they’ll expire.
May 8, 2024 · Patents reward drugmakers for their inventions and, effectively, the large sums of money they invest in research and development. The legal monopoly that patents provide keeps generic copies at bay for many years, even decades, and allows pharmaceutical companies to set higher prices than they otherwise could.
Revolution Medicines firms up Phase 3 trial plans with latest …
Jul 15, 2024 · Revolution Medicines firms up Phase 3 trial plans with latest cancer drug data Updated results show the biotech’s therapy shrank pancreatic tumors in 20% to 25% of study participants, but with high rates of side effects like rash and nausea.
The biopharma industry outlook on 2024: Guarded optimism for a …
Jan 16, 2024 · Guarded optimism seems to be the mood of the biopharmaceutical industry to start 2024.. Last year brought a stock market slide and layoffs for more than 150 drug companies. Financial and regulatory headwinds, like the March collapse of Silicon Valley Bank and a more strident Federal Trade Commission, further weighed on the sector.. There are now some signs …